AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

This morning, AtaiBeckley shared positive topline data from the open-label portion of its Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) in patients with treatment-resistant depression (TRD). The open-label extension (OLE) saw participants offered a second, 12 mg dose of the short-acting psychedelic after the 8-week blinded period during which they received one of three first doses (0.3 mg, 8 mg…

Source